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A B S T R A C T
Background: Gastrointestinal stromal tumours (GISTs) are rare, yet the most common mesenchymal
tumour within the digestive tract. Lack of diagnostic criteria and no speciﬁc code in the ICD system has
prevented epidemiological evaluation except from overt malignant cases in the past. A global estimate of
incidence and disease patterns has thus not been available.
Methods: A systematic literature search of all available population-based studies on GIST published
between January 2000 and December 2014 were reviewed. Descriptive epidemiological data are
presented.
Results: The search found 29 studies of more than 13,550 patients from 19 countries that reported
sufﬁcient data for regional or national population-based statistics. Age at diagnosis ranged from 10 to
100 years, with median age being mid 60s across most studies. Gender distribution was equal across
studies. On average, 18% of patients had an incidental diagnosis (range from 5% to 40%). Anatomical
location of primary tumour in 9747 GISTs demonstrated gastric location as the most frequent (55.6%)
followed by small bowel (31.8%), colorectal (6.0%), other/various location (5.5%) and oesophagus (0.7%).
Most studies reported incidence at 10–15 per million per year. Notably, lowest incidence was in China
(Shanxi province) with 4.3 per million per year. Highest incidence rates were reported also from China
(Hong Kong and Shanghai areas), and in Taiwan and Norway (Northern part), with up to 19–22 per million
per year.
Conclusions: Epidemiology of GIST demonstrates some consistent features across geographical regions.
Whether the reported extreme differences in incidence reﬂect real variation in population risk warrants
further investigation.
ã 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Gastrointestinal stromal tumour (GIST) is the most common
mesenchymal tumour of the gastrointestinal tract [1]. Malignant
GISTs were once viewed as one of the most treatment-refractory
tumours, with very few patients showing clinical response to
conventional chemo- and/or radiation-therapy. Further, mesen-
chymal tumours were not properly recognized as speciﬁc entities
before the emergence of proper diagnostic tools. The recognition of
the interstitial cells of Cajal as the likely precursor cell and,
identiﬁcation of the mutations in c-KIT and platelet-derived
growth factor receptor a (PDGRF-a) further led to increased
understanding of the biology [2,3]. The break of the millennium
saw the ﬁrst reports on successful treatment with imatinib for
metastatic GIST [4,5], which has now evolved into use for recurrentTable 1
Epidemiology of GIST reported in population-based studies.
Author (Refs.) Study population Population Years incl. 
Nilsson et al. [26] Sweden; Western 1.3–1.6 mill 1983–2000 
Tryggvason et al. [27] Iceland; National 300,000 1990–2003 
Goettsch et al. [28] Netherlands; National 16 mill 1995 + 1998
2003
Kim et al. [29] Republic of Korea 48.5 mill 2001–2002 
Steigen and Eide [30] Norway; Northern n.r. 1974–2003 
Chan et al. [31] China, Hong Kong 300,000–
350,000
1995–2003 
Tran et al. [23] USA, SEER data 1992–2000 
Perez et al. [32] USA (SEER and Florida) n.r. 1992–2002 
Rubió et al. [33] Spain; Girona 553,661 1994–2001 
Mucciarini et al. [34] Italy; Modena 633,993 1991–2004 
Tzen et al. [35] Taiwan n.r. 
Mazzola et al. [36] Switzerland; Southern n.r. 1995–2002 
Ahmed et al. [37] UK; Mid Trent n.r. 1987–2003 
Yan et al. [38] Canada, Calgary 958,610 2000–2004
Brabec et al. [39] Czech Republic
and Slovakia
15 mill 2000–2008
Cassier et al. [40] France, Rhone-Alps region 5.96 mill 2005–2006
Monges et al. [41] France; national 62.9 mill 2005 
Cho et al. [42] Korea, nationwide 2003–2004
Hartley et al. [43] Pretoria, South Africa 2.35 mill 2000–2009
Sandvik et al. [44] Norway, Southwestern 300,000 1980–2009 
Giljaca et al. [45] Croatia, western Adriatic region 250,000 1997–2007 







Manrique et al. [47] Lima, Perú n.r. 2002–2010 
Wang et al. [48] Shanxi Province, China 35.9 mill 2011 
Minarik et al. [49] Slovakia 2004–2011 
Rubio-Casadevall et al.
[50]
Spain, northern region (Girona) 1994–2005 
Czech registry et al.
[51]
Czech and Slovak republic,
nationwide
15 mill 2006–2013 
Chiang et al. [52] Taiwan 23.4 mill 1998–2008 
Lv et al. [53] Shanghai, China 30.4 mill 2000–2010 
SEER denotes “Surveillance, Epidemiology, and End Results”.
n.r. denotes “not reported”.; n.a. denotes “not applicable”.
a Reported as mean age.disease and, in adjuvant and neoadjuvant regimens [6–10],
followed by new targeted drugs [11]. Thus, within the past decade,
GISTs have emerged from being poorly deﬁned, treatment-
resistant tumours to a treatable tumour entity used as a cancer
model for multidisciplinary, targeted therapy [12–14].
Although, KIT (CD117) immunohistochemistry is a reliable
diagnostic tool in the diagnosis of GIST [15], the (few) cases of KIT-
negative GISTs, GISTs showing unusual morphology as well as
GISTs which progress during or after treatment with imatinib/
sunitinib can be a challenge for pathologists and clinicians [16].
Further, until the recent awareness of the disease with ensuing
consensus reports [17], no reliable coding or diagnostic practice
has been used in various registries or pathology labs across the
world. Thus, while reports on very large numbers of patients have







288 14.5 1.0 69 (10–92)
57 11.0 1.5 66 (24–89)
– 1169 12.7 n.r. n.r.
747 7.7 1.0 56.3a (10–83)
102 19.0 1.6 66 (32–93)
47 16.8–19.6 1.2 66a (n.r.)
1458 6.8
n.r. 6.9 n.r. n.r.
46 10.9 1.0 63 (26–90)
124 14.2 1.0 69 (30–90)
13.0
14.7 64
185 13.2 0.9 64 (18–93)
 22 6.8 0.7 62a (n.r.)
 278 5.2 1.0 60
 131 11.0 0.75 66 (34–91)
535 8.5–10 0.9 65a(19–93)
 1227 16–22
 54
52 7.4 (5.4–9.4) 0.8 67
31 12.4 0.8 Mean 61.9  12.8 years, range 34–
81
368 13.6 1.0
103 n.r. 1.0 mean 64 yrs, range 30–88
153 4.3 1.2 59 (24–79) years
278
82 12.4 1.0
1107 9.2 1.1 62 yrs (38–79)
2986 11.3–19.7
1923 21.1 1.0 60.05  12.98 years (range: 12–
87 years)
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perspectives is less well described. This is due to many reasons but
most importantly the larger series may be biased in referral pattern
in terms of diagnosis or treatment of those patients with a
malignant potential, overt or metastatic disease [21–23], which
may not reﬂect the true population-based incidence of all GISTs
[24].
Thus, we performed a systematic review to assess the reported
incidence, tumour location, and clinicopathological data in truly
population-based studies.
2. Materials and methods
2.1. Literature search
A systematic search of the PubMed/Medline English literature
from January 2000 until December 31st, 2014 was performed using
the search terms “gastrointestinal stromal tumour”, “GIST”,
“epidemiology”, “incidence”, “population-based”. Case reports,
or reports of less than 20 cases, were excluded. Excluded were also
studies not describing the primary catchment population or region
from which the patients derived, or, if this information could not be
obtained by contacting the authors of identiﬁed articles. Refer-
ences in the identiﬁed articles were searched to identify further
possible studies.
For any region(s) described and deﬁned in a study, but for which
the actual population numbers were not given, the population
statistics denominator was obtained from population statistics
given by the World Bank population data [25].
The literature was searched for reports published after year
2000 only to ensure best possible homogenous comparison inFig. 1. Distribution of anatomical locatiodiagnosis and recognition of GIST. Studies relying on histopathol-
ogy alone (without immunohistochemistry) were excluded.
Studies conﬁrming immunohistochemistry results with or without
mutational analysis were included, but mutational analysis was
not required per se for inclusion. For studies reporting several
papers on the same population, the paper with reported
population-based data on incidence, tumour location and patient
characteristics was included.
2.2. Statistical analysis
Attempt at formal metaanalysis was not done due to the
perceived heterogeneity in the identiﬁed studies. Descriptive data
are presented collectively for those categories were information
could be obtained.
3. Results
The search found 29 studies [23,26–53] from 19 countries that
reported sufﬁcient data for regional or national population-based
statistics. The identiﬁed studies are given in Table 1.
3.1. Incidence and demographic data
The reported incidence shows some variation between the
studies, with studies from Northern-Norway [30], China (Hong
Kong [31] and Shanghai [53]), and Korea [42] reporting incidences
as high as 19–22 cases per million inhabitants, which represents
the upper range limit reported in the world literature. On the other
hand, data from the Shanxi province in China [48], the Czeck
republic and Slovakia [39], and North America (Canada [38] andn of GIST tumors per study cohort.
42 K. Søreide et al. / Cancer Epidemiology 40 (2016) 39–46USA [23]) show a very low incidence between 4.3 and 6.8 per
million. However, most studies report incidences between 10 and
15 cases of GISTs per million. The majority of studies reporting an
increase in incidence over time included material prior to year
2000, thus likely indicating an identiﬁcation bias rather than a true
increase in incidence.
The reported age ranges from 10 to 100 years, with median age
reported in the mid 60s for most studies (Table 1). The gender
distribution shows a fairly consistent equal distribution between
male and females (Table 1).
3.2. Primary GIST location
Most GISTs are found in the stomach, and this is fairly
consistently reported between studies, with some variation
(Fig. 1). No clear time-trend can be found, and the variance in
oesophageal and colorectal GISTs, likely both reﬂects the rare
occurrence and possibly underreported incidence.
The collated information on localization in 9747 GISTs is
presented in the Fig. 2. Gastric location is the most frequent (55.6%)
followed by small bowel (31.8%), with colorectal in 6.0%, other/
various locations in 5.5% and oesophagus in only 0.7% and no info
in 0.2%.
3.3. Clinical presentation of primary GISTs
A total of 15 studies reported on clinical presentation, roughly
split into ‘symptomatic’ disease (81.3%, n = 1997) or ‘incidental’
(asymptomatic, 18.7%) ﬁndings in a total of 2456 patients (Fig. 3).
Data on the speciﬁc symptoms were variable recorded among the
studies and with different categories and deﬁnitions used. Among
the most common symptoms were noted abdominal pain,
gastrointestinal bleeding and obstruction, but a number of other
nonspeciﬁc complaints were reported across studies. (Fig. 3)
3.4. Distribution of size of primary GISTs
Size distribution was reliably presented in 13 studies compris-
ing 3296 patients, for which only 102 patients did not have anyFig. 2. Absolute number of patients with GISinformation on size. As not all studies discerned between the
largest size groups (e.g. not all divided the larger tumours into
those >5 cm but 10 cm, to those >10 cm), the accumulated data
are presented with 3 size groups in Fig. 4. Accumulated data
showed that 49% of tumours where larger than 5 cm, and only 13%
in the <2 cm size-group.
3.5. Distribution of NIH risk categories in primary GISTs
Among the studies that reported NIH risk groups (Fig. 5), the
very low risk GISTs were least frequent (15%), with low,
intermediate and high-risk categories representing 30%, 22%,
and 33%, respectively. Only one study reported the AFIP risk
category, while a number of studies reported mitosis count
categories alone without attributing these ﬁndings to a risk
stratum. Also, studies reported to a very variable degree if they had
cases that would could not be evaluated for risk categories, such as
Cho et al. who noted non-designated in 127 (10.3%) of
1227 patients.
4. Discussion
This systematic review of the available population-based
studies reporting incidence and epidemiological data on GIST is
the ﬁrst attempt at identifying and estimating the global burden of
GISTs. We report the ﬁrst collective data on distribution and
demographics of GISTs, as reported in the worldwide literature.
The estimates of GIST incidence across regions may allow for
assumptions for case accrual and recruitment for future trials and
interventions.
There was a signiﬁcant variation in the reported incidence of
GISTs, which is likely be due to a number of factors. First,
methodological issues are at hand, as the diagnostic criteria have
been in development and improved over time [17,18], and, thus,
variation in diagnosis and recording may have occurred. Secondly,
few countries have established registries that captured all GISTs,
while some cancer registries have collected data on the overt
malign cases. Thus, smaller, incidental and low risk tumours may
be underrepresented in several studies [54,55]. Further, studies ofT per anatomical location across studies.
Fig. 3. Distribution of clinical presentation as symptomatic or incidental across studies.
Fig. 4. Size distribution on presentation per study cohort.
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Fig. 5. Distribution of NIH risk categories per study cohort.
44 K. Søreide et al. / Cancer Epidemiology 40 (2016) 39–46high-incidence from Northern-Norway [30], China (Hong Kong
[31] and Shanghai [53]), and Korea [42] reported incidences up to
22 cases per million inhabitants. In contrast, data from the Shanxi
province in China [48], the Czech republic and Slovakia [39], and
North America (Canada [38] and USA [23]) reported very low
incidences down to 4.3 per million. This 4–5-fold difference in
reported incidence may be explained by differences in identiﬁca-
tion and reporting of data, for example a bias towards reporting
and identiﬁcation of the overtly malignant GISTs in the low-
incidence reports (such as the SEER data from the US). With
development and evolution of GIST speciﬁc registries [51,56–58],
widespread use of the diagnostic criteria [17,18,59], use of
standardized protocols [60] for reporting and more speciﬁc use
of dedicated SNOMED coding, the true epidemiological collection
of GIST data may prove more correct in the near future.
European data on incidence were considered conform to the
reported middle values, with few outliers. Data from North
America (US and Canada) did display some considerable variation,
which may in part be related to reliance on SEER data that usually
captures the more overt malign cases [23,24,38,61]. However, it
appears that this may have improved over time, with most recent
data suggesting about 8 cases per million per year, which is in line
with several European studies. Not surprisingly, most studies
demonstrate an increased risk and higher incidence with increas-
ing age, with age-related incidence reported over 30 per million
per year for those >70 years of age [38,61]. It should also be noted
that incidental ﬁndings increase with new interventions, such as
reported for gastric GISTs investigated in sleeve gastrectomies for
morbid obesity, which is reaching epidemic proportions world-
wide [62]. Also, in areas with population screening, such as for
gastric cancer in Japan, the prognosis appears to be inﬂuenced by
detection of more incidental and smaller GISTs [63]. Further, one
should note that even today all diagnoses of GISTs are not readily
conﬁrmed, as only resected specimens can truly yield a sure tissue-based diagnosis. Many patients with a small lesion and a difﬁcult
location (e.g. small incidental lesion in oesophagus) may be
followed by endoscopic ultrasound techniques, but tissue diagno-
sis may be hard to obtain or not as correct as one would like to
believe [64].
The most extreme variation (from as low as 4 to as high as
22 GISTs per million per year) stems from the Asian studies
reported [31,35,48,52,53]. Whether or not this represent true and
unique differences or just variation in data capture or methodology
remains speculative. However, it warrants further investigation
into possible disease related risk differences in future studies.
Obviously, the advancement in diagnostic assessment as well as
outline of mutational subtypes continue to progress [18,21,65,66].
As most of the studies reported in the current collected series
predated the current knowledge on mutational status and
advancements in molecular classiﬁcation [67,68], it was not
possible to collate such information. It is expected that as methods
evolve and become more widespread, such information will be
more frequently reported and made readily available. Further, risk
groups and prognostic tools continue to evolve and may be more
readily compared across studies in the future [69,70]. Currently,
adjuvant imatinib treatment has become more widespread and
thus, direct comparison of survival curves over time is not justiﬁed
[71,72].
Some limitations deserve mentioning in this study. First, while
we attempted to contact all authors of studies where baseline info
was not stated or unclear, we were unable to make contact with
some authors or, they were not able to give additional needed info
from their health care systems as to the epidemiological aspects of
GIST. Also, several regions were underrepresented in the literature
and consequently regions including several deprived and under-
developed regions in the world, including African countries, the
Middle East region, India and the South Americas were not
represented with epidemiological data, although a few small
K. Søreide et al. / Cancer Epidemiology 40 (2016) 39–46 45studies (non-population based) from these regions were noted in
the literature [47,73–77]. Further, the heterogeneity by which
studies are reported severely hampers collection of all data across
studies. Thus, standard recommendations for reporting epidemio-
logical data should be developed and adhered to in order to better
collate and present high-quality data for comparison. While GIST is
perceived to be a rare disease, it remains the most frequent
mesenchymal tumour of the digestive tract. Further, GIST patients
have had a notable increase in prevalence due to the progress in
surgical and oncological management. Estimates suggest that the
prevalence is over 10-times that of the incidence, with GIST-
survivors now being in the number of 135–155 per million per year
in several studies [26,31,78].
5. Conclusions
This collective review of population-based epidemiological
reports on GIST conﬁrms several features, such as a fairly equal
gender distribution, predominant age in the 60s, over 80% present
with symptoms, and tumours most frequently located in the
stomach and small bowels. The rather large tumour size and high
risk grade reported may point to a bias in selection and recording of
tumours with unfavourable appearance, possibly understating the
true incidence of smaller and more “innocent tumours” [55]. The
variable incidence across regions warrants further investigation
into differences in methodology or true population difference in
disease risk. Future reports should strive to standardize reporting
according to uniform diagnostic and prognostic criteria.
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